Sarah Jessica Parker doesn't watch ‘Sex and the City' or ‘And Just Like That…'
The woman at the center of the 'Sex in the City' franchise can't bring herself to watch it.
Sarah Jessica Parker, who stars in and produced both 'Sex and the City' and its spinoff sequel series 'And Just Like That…,' revealed she hasn't followed the lives of Carrie Bradshaw and her friends on screen.
'Oh my God, no. I don't watch it, never seen it,' Parker told E! News, explaining she doesn't like to watch herself. 'Never seen 'Sex and the City,' most of them.'
Which makes us wonder: Are we the crazy ones because we have?
'Sex and the City' is based the 1996 book of the same name by Candace Bushnell, which was an anthology of her newspaper columns with the same title. The HBO series ran from 1998 to 2004 and also inspired two films. (HBO and CNN are both part of Warner Bros. Discovery.)
The original show focused on Bradshaw, a columnist who wrote about sex and relationships and her three closest friends: Charlotte York (played by Kristin Davis); Miranda Hobbes (Cynthia Nixon); and Samantha Jones (Kim Cattrall).
'And Just Like That…' premiered in December 2021, minus Cattrall, who declined to return to the franchise, though she did make a bit of a cameo during the Season 2 finale.
Parker also revealed that her 13-year-old twins, Tabitha and Marion, whom she shares with husband and fellow actor Matthew Broderick, have also not seen the franchise. Their 22 year-old son, James Wilkie, however, has seen a few episodes.
'I think it's very odd for them to yet let it into their viewing queue,' Parker explained. 'Even for James Wilkie, he started by coming to the premiere of 'And Just Like That,' then he started watching the show but school work got in the way. But it's all available for them some day if they want it, they'll get no pressure from me.'
The third season of 'And Just Like That…' premieres Thursday.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
26 minutes ago
- Medscape
Wildfire Smoke Linked to Respiratory Admissions in Seniors
Among older adults in the western United States, exposure to high concentrations of smoke-related fine particulate matter (PM2.5) was associated with increased rates of hospitalizations for respiratory diseases, with weaker but suggestive ties to cardiovascular hospitalizations. METHODOLOGY: Researchers carried out a retrospective cohort study to analyze the association between exposure to smoke-specific PM2.5 and cause-specific hospitalizations in older adults in the United States. They used inpatient claims data of 10,369,361 Medicare beneficiaries (mean age, 74.7 years; 53.1% women) across 11 western United States during wildfire seasons from 2006 to 2016, with 57,974,120 person-months of follow-up. The causes of unscheduled hospitalizations were inferred from International Classification of Diseases, Ninth Revision, Clinical Modification codes and classified into various disease categories. codes and classified into various disease categories. Daily concentrations of surface-level smoke-specific PM2.5 were estimated through machine learning models that utilized ground measurements, satellite data, and reanalysis data sources. The associations between causes of hospitalization and smoke-specific PM2.5 were characterized by examining daily county-level rates of unscheduled hospitalization by disease category, modeling hospitalization rates according to same-day and prior-week smoke-specific PM2.5 exposure. TAKEAWAY: The leading cause of unscheduled hospitalizations was cardiovascular disease, with a mean daily rate of 7.92 per 100,000 persons, followed by digestive system disease at 3.62 and respiratory disease at 3.53 per 100,000 persons. Respiratory hospitalizations increased as smoke-specific PM2.5 exceeded 25 μg/m 3 , with average daily rates increasing by 2.40 (95% CI, 0.17-4.63) per 100,000 persons when PM2.5 levels rose from 0 to 40 μg/m 3 over a week. , with average daily rates increasing by 2.40 (95% CI, 0.17-4.63) per 100,000 persons when PM2.5 levels rose from 0 to 40 μg/m over a week. Hospitalizations due to cardiovascular diseases were unrelated to smoke-specific PM2.5 at exposure levels < 20 μg/m 3 but showed an increasing trend at higher concentrations. but showed an increasing trend at higher concentrations. No significant associations were seen for hospitalizations related to injuries, digestive issues, neuropsychiatric conditions, or endocrine disorders. IN PRACTICE: 'This information can be used by both policymakers and clinicians to design policies and guidelines to protect vulnerable older adults from the escalating health threats posed by wildfire smoke,' the authors wrote. SOURCE: This study was led by Sofia L. Vega, Harvard T.H. Chan School of Public Health, Boston. It was published online on April 30, 2025, in JAMA Network Open . LIMITATIONS: Estimating concentrations of smoke-specific PM2.5 proved challenging due to the lack of direct measurements. County-level exposure measures may not have accurately reflected the exposures experienced by individual residents. This study did not include information on wildfires from recent years when their intensity increased. DISCLOSURES: This study was supported by the Harvard Climate Change Solutions Fund and grants from the National Institutes of Health. One author reported receiving support through an environmental fellowship at the Harvard University Center. The authors reported having no conflicts of interest.
Wall Street Journal
28 minutes ago
- Wall Street Journal
Stocks to Watch on Tuesday: Paramount, TSMC, Dollar General
🔎 Paramount (PARA): The entertainment conglomerate, which is in negotiations to settle an election-interference lawsuit by President Trump, nominated three new directors to its board. The CBS owner scheduled its shareholder meeting for July 2. 🔎 TSMC (TSM): The global chipmaker faces limited impact from tariffs, as levies are typically borne by importers, Chief Executive C.C. Wei said at a shareholder meeting. He guided for revenue and earnings to hit new highs this year. ↗️ Wolfspeed (WOLF): The semiconductor company rose in brisk trading off-hours. The stock has been volatile in recent weeks. The Wall Street Journal reported in late May that Wolfspeed was preparing to file for bankruptcy.
Medscape
31 minutes ago
- Medscape
Systemic Psoriasis Therapy Linked to Less Dementia
SAN DIEGO — While psoriasis is linked to higher rates of dementia, a new study suggested that older patients with psoriasis on systemic treatments may have a much lower risk than those not treated systemically. In fact, the research hints — but doesn't prove — that the medications could lower the dementia risk even below that of the general population. The study, which retrospectively evaluated US medical records of people aged 65-95 years from 2004 to 2024, found that patients with psoriasis on systemic therapies (n = 14,679) had a lower risk of developing dementia than those not on systemic treatment (n = 39,601) and lower than a matched general population group (5.77 million). The adjusted odds ratios (aORs) for the treated psoriasis group vs the untreated group were 0.49 (0.39-0.61) for Alzheimer's disease, 0.65 (0.51-0.83) for vascular dementia, and 0.60 (0.53-0.68) for nonvascular dementia. For the treated group vs the matched general population, the aORs were 0.69 (0.54-0.86), 0.85 (0.65-1.10), and 0.85 (0.75-0.97), respectively. The findings, presented at the Society for Investigative Dermatology (SID) 2025 Annual Meeting, are too preliminary to affect clinical practice. But the study does add to 'a growing body of evidence linking chronic inflammation to neurodegeneration,' study lead author Madison Olexson, a dermatology research fellow at Eastern Virginia Medical School, Norfolk, Virginia, told Medscape Medical News . 'It reinforces [how] treating systemic diseases like psoriasis may not only improve cutaneous symptoms but may have extra-cutaneous benefits as well,' she said. Sparse Data on Systemic Treatments and Psoriasis Several international reports have linked psoriasis with dementia, including a 2019 study that found an elevated risk associated with the skin disease and vascular dementia (hazard ratio [HR], 1.73; 95% CI, 1.21-2.47) and a 2023 study that identified an increased risk for dementia (HR, 1.24; 95% CI, 1.14-1.35). Also, a 2019 study linked dementia to a higher risk for psoriasis (OR, 1.46). Other autoimmune disorders such as rheumatoid arthritis and inflammatory bowel disease have also been linked to higher incidence and risk for cognitive impairment and dementia, Olexson said. 'This is believed to be linked to systemic inflammation and the sustained activity of proinflammatory cytokines such as [tumor necrosis factor] TNF alpha and [interleukin 17] IL-17, which can affect the brain and potentially lead to neurodegeneration. However, the exact mechanisms remain unclear.' She added that 'it's still a mystery whether psoriasis alone drives the development of dementia or if the increased likelihood is due to shared comorbidities or overlapping inflammatory pathways. Furthermore, we don't yet fully understand whether treatments provide direct cognitive protection or how long treatment needs to continue for maximal benefit.' Biologics and Non-Biologics Both Linked to Benefit The researchers launched the new study 'to address the limited and inconsistent data on whether psoriasis associates with dementia outcomes and systemic treatments for psoriasis could influence the likelihood of developing dementia,' Olexson said. The study retrospectively tracked patients via the TriNetX research network database. Before propensity score matching, the mean age was 66.6 ± 8.9 years for non-treated patients and 67.8 ± 9.0 years for the general population. Respectively, the groups were 42.8% and 51.7% women and 65.9% and 72.6% White. Data for the treated psoriasis group were not provided, but Olexson said their characteristics were similar. The study included both biologic medications, which target specific immune pathways, and non-biologic systemic treatments. Patients were treated for a median of 4 years (for both). The biologics were adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, ustekinumab, guselkumab, tildrakizumab, risankizumab, secukinumab, ixekizumab, and brodalumab. The non-biologic treatments were methotrexate, apremilast, acitretin, and ultraviolet phototherapy. Both drug classes were linked to lower risks for dementia at roughly the same rates, but it was not clear if specific medications may have greater effects. Less Inflammation May Protect Against Dementia The adjusted incidence rates of Alzheimer's disease were 1.9% vs 1.2% in the non-psoriasis group vs the treated psoriasis group. For vascular dementia, the rates were 1.2% vs 0.74%, respectively. For nonvascular dementia, they were 5.4% vs 3.7%, respectively. For untreated patients with psoriasis vs treated patients with psoriasis, the adjusted incident rates were 1.7% and 0.84% for Alzheimer's disease, 1.1% and 0.72% for vascular dementia, and 5.1% and 3.1% for nonvascular dementia, respectively, which Olexson reported were statistically significant differences. 'Systemic therapies likely reduce neuroinflammation by suppressing inflammatory cytokines like TNF alpha and IL-17, both of which have been implicated in neurodegenerative processes,' Olexson said. 'These cytokines can disrupt the blood-brain barrier, promote amyloid beta accumulation, and impair neuronal function. By modulating this inflammatory cascade, systemic treatments may protect against or slow the onset of dementia.' Findings Are 'Intriguing' but Not Definitive Asked to comment on the results, Steven R. Feldman, MD, PhD, professor of dermatology, Wake Forest University, Winston-Salem, North Carolina, who was not involved in the study, noted that while the findings are 'intriguing,' they come with caveats because of the observational study design. 'If patients with dementia aren't bothered by their psoriasis or aren't given biologics for that or some other reason, getting a biologic might be associated with less dementia,' he said in an interview. 'It may be that having or not having dementia determines to some degree who gets a biologic, not that taking a biologic determines who gets dementia.' Olexson agreed that the observational design has limitations. While cohorts were matched by demographics, body mass index, and several comorbidities, she said other factors such as disease severity, socioeconomic status, and access to care could play a role in the findings. What's next? Moving forward, Olexson said, 'We have plans to conduct prospective studies related to psoriasis and cognitive health at our institution.'
